Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted…
<!-- Name:DistributionId Value:8791865 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Atopic
Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor
NEW ORLEANS -- A novel lower-concentration topical formulation of the PDE4 inhibitor roflumilast produced rapid improvement in…
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in…
<!-- Name:DistributionId Value:8790647 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic…
<!-- Name:DistributionId Value:8790795 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Clinical Challenges: Topical Therapy for Atopic Dermatitis in Adults
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease that occurs most frequently in children, but also affects…
Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis
Elana Gotkine
THURSDAY, March 16, 2023 (HealthDay News) -- For adults and adolescents with moderate-to-severe atopic dermatitis, 16 weeks of…
AI model helps atopic dermatitis patients diagnose complications and malignant…
A team of dermatologists has developed an artificial intelligence (AI) model that empowers atopic dermatitis (AD) patients to detect complications from bacterial or viral infections and…
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study…
<!-- Name:DistributionId Value:8756146 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Dupilumab Delivers in Erythrodermic Atopic Dermatitis
Patients with severe erythrodermic atopic dermatitis (AD) had significant improvements with…
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat…
<!-- Name:DistributionId Value:8737493 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…